Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability
暂无分享,去创建一个
Q. Hu | Jianmin Wang | S. Glenn | Lei Wei | S. Battaglia | M. Long | R. Jain | S. George | Yuanquan Yang | P. Singh | Nicholas D. Hutson | Bo Xu
[1] J. Moser,et al. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[2] Z. Pursell,et al. POLE proofreading defects: Contributions to mutagenesis and cancer. , 2019, DNA repair.
[3] G. Pond,et al. Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs). , 2019, Journal of Clinical Oncology.
[4] L. Thomas,et al. Plasmacytoid variant urothelial carcinoma: Clinicopathologic outcomes and experience with neoadjuvant chemotherapy. , 2019, Journal of Clinical Oncology.
[5] T A Chan,et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] P. Hegde,et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.
[7] N. Schultz,et al. Defining the DNA damage repair (DDR) genomic landscape of urothelial carcinoma of the bladder (UCB). , 2018 .
[8] I. Ostrovnaya,et al. Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC). , 2018 .
[9] T. Chan,et al. ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis , 2017, Cancer Immunology Research.
[10] Harini Veeraraghavan,et al. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient , 2017, Cell.
[11] G. Iyer,et al. Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. , 2017 .
[12] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[13] Roland Eils,et al. Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..
[14] Jeremy J Jay,et al. Lollipops in the Clinic: Information Dense Mutation Plots for Precision Medicine , 2016, PloS one.
[15] M. Nielsen,et al. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets , 2016, Genome Medicine.
[16] B. Taylor,et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer , 2016, Nature Genetics.
[17] Ian Tomlinson,et al. A panoply of errors: polymerase proofreading domain mutations in cancer , 2016, Nature Reviews Cancer.
[18] C. Morrison,et al. Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib , 2015, Cold Spring Harbor molecular case studies.
[19] M. Nielsen,et al. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification , 2015, Immunogenetics.
[20] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[21] F. Sinicrope,et al. Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer , 2015, Current Treatment Options in Oncology.
[22] Z. Modrušan,et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.
[23] Yang Xu,et al. MutS homologue hMSH4: interaction with eIF3f and a role in NHEJ-mediated DSB repair , 2013, Molecular Cancer.
[24] C. Her,et al. Send Orders of Reprints at Reprints@benthamscience.net Muts Homologues Hmsh4 and Hmsh5: Genetic Variations, Functions, and Implications in Human Diseases , 2022 .
[25] I. Adzhubei,et al. Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.
[26] Kenny Q. Ye,et al. An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.
[27] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[28] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[29] Kenneth H. Buetow,et al. Bioinformatics Applications Note Sequence Analysis Bambino: a Variant Detector and Alignment Viewer for Next-generation Sequencing Data in the Sam/bam Format , 2022 .
[30] H. Raventós,et al. In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation , 2010, Journal of molecular medicine.
[31] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[32] E. Friedman,et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Tatiana A. Tatusova,et al. NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins , 2004, Nucleic Acids Res..
[34] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[35] Wei Yang,et al. Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA , 2000, Nature.
[36] P. Ross-Macdonald,et al. Mutation of a meiosis-specific MutS homolog decreases crossing over but not mismatch correction , 1994, Cell.
[37] O. Lund,et al. NetMHCpan, a method for MHC class I binding prediction beyond humans , 2008, Immunogenetics.
[38] Stefan Britsch,et al. The neuregulin-I/ErbB signaling system in development and disease. , 2007, Advances in anatomy, embryology, and cell biology.
[39] S. Britsch. Introduction: Molecular control of development , 2007 .
[40] Claude-Alain H. Roten,et al. Theoretical and practical advances in genome halving , 2004 .
[41] Elizabeth M. Smigielski,et al. dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..